Enliven Therapeutics Appoints Biopharma Veteran Scott Garland to Board, Bolstering Commercialization Expertise for Phase 3

summarizeSummary

Enliven Therapeutics appointed Scott Garland, a biopharma commercialization expert, to its Board, signaling a strategic focus on late-stage development and commercialization for its lead drug candidate, ELVN-001.

check_boxKey Events

• Strategic Director Appointment

  Scott Garland, a biopharma executive with over 30 years of commercial leadership experience, was appointed as a Class I director and Chair of the Nominating and Corporate Governance Committee, effective January 7, 2026.

• Focus on Commercialization Readiness

  The appointment is part of Enliven's strategic transition to late-stage development and commercialization of ELVN-001, with a planned Phase 3 trial initiation in 2026. Garland's expertise in drug launches and scaling organizations is highly relevant to this phase.

• Director Compensation

  Mr. Garland will receive annual cash compensation of $50,000 and was granted stock options with a grant date fair value of approximately $650,000, vesting monthly over 36 months.

• Non-Contentious Director Resignation

  Andrew Phillips, Ph.D., resigned from the Board and its committees, effective January 7, 2026. His resignation was not due to any disagreement with the company's operations, policies, or practices.

auto_awesomeAnalysis

Enliven Therapeutics has strategically strengthened its Board of Directors by appointing Scott Garland, a seasoned biopharma executive with extensive experience in oncology and hematology commercialization. This move is critical as the company prepares to advance its lead product candidate, ELVN-001, into a pivotal Phase 3 trial in 2026 and moves towards potential commercialization. Garland's expertise in scaling organizations and leading commercial teams is directly aligned with Enliven's stated transition to late-stage development. The resignation of Andrew Phillips, Ph.D., was noted as non-contentious, indicating a planned evolution of the board rather than a disagreement.